Dr. Kim Dong Bin, Honorary Fellow at Monash University and the Hawthorn Medical Research Institute, Australia, at the invitation of the School of Medicine, delivered an academic report on October 23 in Conference Room 437. The event was hosted by Dr. Zhang Yuzhu, Assistant Dean of the School of Medicine and representative from Taizhou Central Hospital (Taizhou University Affiliated Hospital), with over 60 faculty and students attending.

Dr. Kim Dong Bin delivering his academic report

In his report titled “The T-VLP Vaccine: Preventing and Treating Various Cancers,” Dr. Kim shared insights from his decade-long collaboration with Professor Jonathan Sprent, an international authority in cellular immunology, presenting their latest findings on cancer genesis, prevention, and treatment. He analyzed current misconceptions in cancer vaccine development, recounted his team’s research journey, challenges, and breakthroughs, and introduced recent innovation: engineering cancer cells into effective anti-cancer vaccines, achieving 100% prevention and cure rates in early animal trials, heralding a new direction for cancer immunotherapy.

Dr. Kim with faculty representatives

This event provided a rare opportunity for direct interaction with a cellular immunology expert. It also updated medical students on the latest advances in cancer vaccine development and immunotherapy, broadening perspectives for enhancing medical science innovation and entrepreneurship capabilities.

Expert Profile:

Dr. Kim Dong Bin is a cellular immunologist with over 20 years of international experience in cancer vaccine development and immunotherapy. His research, conducted in South Korea (POSTECH), Australia (Garvan Institute of Medical Research/UNSW, Hawthorn Medical Research Institute/Monash University), focuses on novel cancer vaccine platforms, particularly virus-like particle (VLP)-based approaches and cytotoxic T lymphocyte (CTL) expansion.